QTRX - クアンテリックス （Quanterix Corporation） クアンテリックスQTRXのチャート
QTRXの企業情報
| symbol | QTRx |
|---|---|
| 会社名 | Quanterix Corp （クアンテリックス） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クワンテリックス(Quanterix Corporation)は生命科学の研究と診断用超高感度デジタル・イムノアッセイ・プラットフォームとツールを開発する。同社はタンパク質バイオマーカーを検出する単一分子測定を使用する単一分子アレイ（Simoa）プラットフォームを提供する。同社はまた早期検出、モニタリング、予後および疾患の予防のために、新規治療法および診断薬を開発することに集中する。Simoaは研究および臨床試験アプリケーションに重点を置いて、タンパク質検出感度が可能な酵素結合免疫吸着アッセイ（ELISA）技術を促進する。同社はまた、脳傷害、心臓病、癌と他の感染症の研究と診断に注力する。同社は多重化およびカスタムアッセイ機能を備えた自動イムノアッセイプラットフォームであるSimoa HD-1アナライザーを提供する。 クアンテリックスは米国のライフサイエンス企業。超高感度デジタル免疫測定プラットフォ―ムの開発・販売を手掛ける。同社が開発した高感度たんぱく質検出プラットフォ―ム「Simoa」のテクノロジ―は、腫瘍、神経・心臓疾患、炎症および伝染病を含む治療分野での重要なバイオマ―カ―を精密に分析することを可能とする。本社所在地はマサチュ―セッツ州レキシントン。 Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. |
| 本社所在地 | 113 Hartwell Avenue Lexington MA 02421 USA |
| 代表者氏名 | Kevin Hrusovsky ケヴィン・ヒューロソフスキー |
| 代表者役職名 | Executive Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 617-301-9400 |
| 設立年月日 | 39173 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 126人 |
| url | www.quanterix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/qtrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -27.02300 |
| 終値（lastsale） | 18 |
| 時価総額（marketcap） | 397793646 |
| 時価総額 | 時価総額（百万ドル） 398.23560 |
| 売上高 | 売上高（百万ドル） 28.48700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 345.36660 |
| 当期純利益 | 当期純利益（百万ドル） -30.48900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Quanterix Corp revenues increased 53% to $16.2M. Net loss applicable to common stockholders decreased 5% to $14.5M. Revenues reflect North America segment increase from $3.3M to $9.6M EMEA segment increase from $1.6M to $5.2M. Lower net loss reflects Research_Development Expense - Balanci decrease of 12% to $7.1M (expense) Interest expense net decrease of 95% to $24K (expense). |
QTRXのテクニカル分析
QTRXのニュース
Quanterix (QTRX) presents at Barclays Global Healthcare Conference - Slideshow 2023/03/17 18:58:56 Seeking Alpha
The following slide deck was published by Quanterix Corporation in conjunction with this event.
Quanterix''s Return On Capital Employed Insights 2023/03/09 14:47:38 Benzinga
According to data from Benzinga Pro, during Q4, Quanterix ''s (NASDAQ: QTRX ) reported sales totaled $25.82 million. Despite a 47.01% increase in earnings, the company posted a loss of $18.58 million. Quanterix collected $26.65 million in revenue during Q3, but reported earnings showed a $35.06 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
Quanterix to Participate in Barclays Global Healthcare Conference 2023/03/08 21:30:00 Wallstreet:Online
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:35 p.m., EDT. In addition, the company will also host in-person one-on-one meetings with institutional investors on March 15.
A stock that deserves closer examination: Quanterix Corporation (QTRX) 2023/03/07 16:24:00 US Post News
A share of Quanterix Corporation (NASDAQ:QTRX) closed at $13.59 per share on Monday, up from $12.12 day before. While Quanterix Corporation has overperformed by 12.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QTRX fell by -56.87%, with highs and lows ranging from $31.87 to $6.31, […]
Quanterix Corp. PT Raised to $13 at Canaccord Genuity 2023/03/07 12:39:02 Investing.com
https://www.investing.com/news/pro/quanterix-corp-pt-raised-to-13-at-canaccord-genuity-432SI-3023895
Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference 2023/01/03 21:00:00 Business Wire
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Thursday, Jan. 12, 2023, at 12 p.m., PST and will be made available to attendees and the general public. In addition to the session, the company will also be hosting one-on
Quanterix’s Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022/12/05 21:36:00 Wallstreet:Online
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022/12/05 21:36:00 Business Wire
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022. In a historic moment in the fight
Was anything positive for Quanterix Corporation (QTRX) stock last session? 2022/11/15 13:54:00 US Post News
In Monday’s session, Quanterix Corporation (NASDAQ:QTRX) marked $12.84 per share, up from $12.68 in the previous session. While Quanterix Corporation has overperformed by 1.26%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QTRX fell by -77.37%, with highs and lows ranging from $57.55 to $6.31, whereas […]
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum 2022/11/10 21:30:00 Kwhen Finance
Quanterix’s Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022/12/05 21:36:00 Wallstreet:Online
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022/12/05 21:36:00 Business Wire
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022. In a historic moment in the fight
Was anything positive for Quanterix Corporation (QTRX) stock last session? 2022/11/15 13:54:00 US Post News
In Monday’s session, Quanterix Corporation (NASDAQ:QTRX) marked $12.84 per share, up from $12.68 in the previous session. While Quanterix Corporation has overperformed by 1.26%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QTRX fell by -77.37%, with highs and lows ranging from $57.55 to $6.31, whereas […]
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum 2022/11/10 21:30:00 Kwhen Finance
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum 2022/11/10 21:30:00 Wallstreet:Online
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 at 4:30 p.m. EST in Boston, MA. Toloue will also host